Clinical trial NCT02341378: Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis
Official title: A Multicenter, Single-blind, Phase 2A Clinical Trial to Evaluate the Efficacy and Safety of TissueGene-C, a Cell-mediated Gene Therapy, in Degenerative Arthritis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Degenerative Arthritis
Keywords: chondrocyte cells
Osteoarthritis
gene therapy
Lead sponsor: Kolon Life Science
Sponsor class: INDUSTRY
First posted: 2015-01-19
Enrollment: 28
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the efficacy and safety of the intra-articular injection of TissueGene-C in patients with degenerative arthritis of the knee

Detailed description: TissueGene-C is a biological new drug which consists of non-transduced chondrocytes and transduced chondrocytes that express Transforming Growth Factor(TGF)-b1 to regenerate the damaged cartilage.

During the clinical trial Phase 2A, we compare low dose or high dose TissueGene-C in 6 months trial with 28 outpatients who have degenerative arthritis. The patients are randomized to two dose levels of TisssueGene-C by 1:1 ratio, and they are monitored and recorded for alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.

Eligibility criteria: Inclusion Criteria:

1. Male or female, aged 45 years or more
2. With grade 4 degenerative arthritis of the knee \[based on the International Cartilage Repair Society(ICRS) evaluation criteria from the MRI results\]
3. With less than 6 cm2major lesions
4. With major lesions (grade 4) concentrated in only one section of the knee and considered the main cause of the clinical symptoms
5. Unresponsive to conventional symptomatic treatment
6. Healthy and with no major physical examination, hematology, serum chemistry, and urine test findings and no significant medical history
7. Agreed to use an effective contraceptive method during the study period
8. Voluntarily agreed to participate in this study and signed the Informed Consent Form

Exclusion Criteria:

1. Abnormal screening laboratory test (hematology, serum, and urine test) findings
2. Took anti-inflammatory medications (prescribed or over-the-counter), including natural medicines, within 14 days before the injection of the investigational product
3. Took antirheumatic drugs (e.g., methotrexate or antimetabolites) within three months before enrollment in this study
4. Has a history of drug abuse within one year from the enrolment, or has positive results in the urine drug test or serum alcohol test at the screening visit
5. Received an injection in the target knee within two months before enrollment in this study
6. Pregnant or breastfeeding female
7. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, and synovial chondromas)
8. With a current infectious disease, including HIV or hepatitis
9. Has any of the following clinically significant diseases:

   * heart disease \[e.g., myocardial infarction, arrhythmia, other serious heart disease, coronary artery bypass graft (CABG)\]
   * kidney disease (e.g., chronic renal failure, glomerulonephritis)
   * liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)
   * endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)
   * insulin-dependent diabetes mellitus
   * medical history of or current malignant tumor
   * In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests:

     * Leukemia: White Blood Cell level in the hematology
     * Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma : Alkaline phosphatase level in the hematology
10. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study
11. Considered by the investigator inappropriate for participation in this study

Primary outcomes:
measure: Changes in IKDC Subjective Knee Evaluation
timeFrame: Week 0, 12 and 24
Secondary outcomes:
measure: Changes in WOMAC scores
timeFrame: Week 0, 12 and 24
measure: Changes in 100 mm-VAS
timeFrame: Week 0, 12 and 24
measure: Comparative Evaluation of Knee MRI
timeFrame: Week 0, 12 and 24
measure: Number of Participants with Adverse Events
timeFrame: Week 0, 2, 4, 12 and 24
measure: Evaluation of Physical examination and laboratory tests
timeFrame: Week 0, 2, 4, 12 and 24
Other outcomes:
Locations:
city: Gangnam-gu
country: Korea, Republic of
facility: Samsung Medical Center
state: Seoul
city: Seoul
country: Korea, Republic of
facility: Seoul National Univ. Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Chul-won Ha, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Seoul National University Hospital
name: Myung-chul Lee, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ha CW, Cho JJ, Elmallah RK, Cherian JJ, Kim TW, Lee MC, Mont MA. A Multicenter, Single-Blind, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of a Cell-Mediated Gene Therapy in Degenerative Knee Arthritis Patients. Hum Gene Ther Clin Dev. 2015 Jun;26(2):125-30. doi: 10.1089/humc.2014.145. Epub 2015 Apr 17.